Pharmafile Logo
Pharmafocus logo
Advanced Search

heart failure

Showing 15 posts of 32 posts found.

novartis_outside_1

Novartis’ Entresto helps preserve kidney function in chronic heart failure patients

April 16, 2018
Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in …

News
shutterstock_92671375

Teva spared payout to GSK over patent infringement dispute

March 29, 2018
Sales and Marketing Coreg, GSK, GlaxoSmithKline, Teva, carvedilol, heart failure, pharma

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that …

News
choles

Battling misinformation on the world’s biggest killer

August 14, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing cardiovascular disease, cholesterol, healthcare, heart disease, heart failure, medicine, pharma, pharmaceutical

Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of …

Feature
heart_money

Heart failure market to quadruple in ten years to $16 billion

July 6, 2017
Sales and Marketing GlobalData, Novartis, heart failure

New research from intelligence firm GlobalData has indicated that the market for heart failure drugs is forecast to expand by …

News

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016
Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …

News
novartis_outside_1

Novartis’ heart failure drug Entresto gets top US, EU recommendation

May 23, 2016
Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation

Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US …

News
celltherapy

Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing

UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …

News
entresto

NICE gives green light to Novartis’s heart drug Entresto

April 27, 2016
Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients

NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …

News
novartissunlight_copy

Novartis’s heart failure drug given final recommendation by NICE

March 21, 2016
Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug

The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …

News
Novartis image

Novartis earns provisional NICE yes for Entresto

December 11, 2015
Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure

NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …

News

Novartis’ new heart failure medicine recommended for EU approval

September 25, 2015
Medical Communications, Research and Development Entresto, Novartis, eams, heart failure

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News
Novartis image

Novartis wins US nod for new heart drug

July 8, 2015
Research and Development, Sales and Marketing Entestro, FDA, LCZ696, Novartis, ejection fraction, heart failure, reduced ejection fraction, sacubitril

The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …

News
BMS image

BMS enters gene therapy development deal

April 7, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure

Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …

News

Novartis emphasises pharma growth

June 19, 2014
Sales and Marketing Novartis, breezhaler, dermatology, heart failure, oncology, respiratory

Novartis is to grow its pharma business by focussing on five key areas and predicts that it will have 14 …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025